Partial Epigenetic Reprogramming (in vivo OSK / OSKM) as Long-Horizon Therapeutic Direction: First IND Cleared, Clinical Validation Years Away

Partial epigenetic reprogramming is a long-horizon research direction that has produced strong preclinical results in mouse models; the first FDA IND clearance for a clinical program was issued in late 2024, with no human efficacy or safety data publicly available as of 2026.

Type

evidence-claim

Domain

h03_epigenetic_alterations

Grade

C+

License

CC BY-NC 4.0

card_id

L-015

hallmarks

h03_epigenetic_alterations

cluster

clinical_translation

primary_disease_area

longevity_general

evidence_tier

C+

evidence_anchor_count

5

intake_round

R23

intake_date

2026-05-26

related_experts

related_biomarkers

related_interventions

related_trials

collection_pages

/research/hallmarks/h03-epigenetic-alterations,/research/interventions/partial-reprogramming

LongProof Longevity Dynamic · LIGHT HOPE / x1000.ai · longevity.x1000.ai · 2026 · source

Read-only aggregated view. Longevity Evidence is the source of record; this catalog shows provenance as-is — no ratings, no reviews.